Determinants of prognosis in metastatic urothelial carcinoma: a review of the literature

Abstract

The treatments for metastatic urothelial carcinoma (mUC) have advanced substantially since 2016. Prognostic tools have been used to inform clinical trial designs and treatment decisions. Historically, prognostic tools were developed for mUC based on older clinical trials involving cytotoxic chemotherapy. As novel therapies emerged, there are studies investigating prognostic factors in the era of immune checkpoint inhibitors (ICI), antibody-drug conjugates, and targeted therapies. This review aims to highlight prognostic factors in mUC and their potential in clinical decision-making and research. In the setting of chemotherapy, patient performance status, site of metastatic burden, and specific laboratory findings were found to have prognostic value in mUC. In the era of ICI, newer models identified variables such as neutrophil to lymphocyte ratio, platelet count, and lactate dehydrogenase to also have potential prognostic value. In addition to clinical biomarkers, molecular biomarkers, such as PD-L1 assay and fibroblast growth factor receptor 2 and 3 genomic testings, may have promising prognostic and predictive implications. Current methods of identifying clinical and molecular prognostic factors involve clinician insight. As large complex datasets emerge, machine learning and artificial intelligence may help data analysis and detect important prognostic features. With careful validation, such machine learning-based strategies may help create more robust prognostic and/or predictive models in the future.

Keywords

Bladder cancer / biomarkers / health outcomes / nomogram / prediction / prognosis / urothelial carcinoma / urinary tract cancers

References

[1] American Cancer Society. Key statistics for bladder cancer. Available from: https:// www.cancer.org/cancer/bladder-cancer/about/key-statistics.html [Last accessed on 3 Aug 2022].

[2] Sonpavde G,Gao C.Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors.J Urol2020;204:1173-9 PMCID:PMC7655635

[3] Khaki AR,Diamantopoulos LN.A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors.Eur Urol Oncol2021;4:464-72 PMCID:PMC8169524

[4] Khaki AR,Prasad V.Clinical risk during the evaluation of genomic risk for hormone-sensitive breast cancer: ignoring valuable data.J Natl Compr Canc Netw2019;17:1456-8

[5] Harrell FE.Evaluating the yield of medical tests.JAMA1982;247:2543

[6] Harrell FE,Mark DB.Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.Statist Med1996;15:361-87

[7] Oken MM,Tormey DC.Toxicity and response criteria of the Eastern Cooperative Oncology Group.J Clin Oncol1982;5:649-656

[8] Karnofsky performance status - an overview|sciencedirect topics. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/karnofsky-performance-status [Last accessed on 3 Aug 2022]

[9] Loehrer PJ Sr,Elson PJ.A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.J Clin Oncol1992;10:1066-73

[10] Saxman SB,Einhorn LH.Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.J Clin Oncol1997;15:2564-9

[11] von der Maase H,Roberts JT.Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.JCO2005;23:4602-8

[12] Bellmunt J,Paz-Ares L.Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.Cancer2002;95:751-7

[13] Stadler WM,von der Maase H.Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.Urol Oncol Semin Origin Investigat2002;7:153-7

[14] Sonpavde G,Fougeray R.Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.Eur Urol2013;63:717-23 PMCID:PMC4127896

[15] Bajorin DF,Mazumdar M.Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.J Clin Oncol1999;17:3173-81

[16] Bellmunt J,Fougeray R.Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.J Clin Oncol2010;28:1850-5

[17] Galsky MD,Krege S.Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.Cancer2013;119:3012-9

[18] Galsky MD,Krege S.Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.Urol Oncol2014;32:48.e1-8

[19] Kobayashi T,Kojima T.Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.Cancer Sci2021;112:760-73 PMCID:PMC7893997

[20] Ruiz-Bañobre J,Fernández-Calvo O.Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study.ESMO Open2021;6:100090 PMCID:PMC7980066

[21] Hopkins AM,Karapetis CS,Sorich MJ.Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab.Clin Cancer Res2020;26:5487-93

[22] Nassar AH,Jegede O.A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.Br J Cancer2020;122:555-63 PMCID:PMC7028947

[23] Teutsch SM,Palomaki GE.The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP Working Group.Genet Med2009;11:3-14 PMCID:PMC2743609

[24] Hayes DF.Biomarker validation and testing.Mol Oncol2015;9:960-6 PMCID:PMC5528748

[25] Neumann MHD,Krahn T.ctDNA and CTCs in liquid biopsy - current status and where we need to progress.Comput Struct Biotechnol J2018;16:190-5 PMCID:PMC6024152

[26] Flaig TW,van Bokhoven A.Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.Urology2011;78:863-7 PMCID:PMC3190033

[27] Abrahamsson J,Engilbertsson H.Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival.Urol Oncol2017;35:606.e9-606.e16

[28] Fina E,Giannatempo P.Clinical significance of early changes in circulating tumor cells from patients receiving first-line cisplatin-based chemotherapy for metastatic urothelial carcinoma.Bladder Cancer2016;2:395-403 PMCID:PMC5181661

[29] Powles T,Davarpanah N.ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.Nature2021;595:432-7

[30] Vandekerkhove G,Annala M.Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer.Clin Cancer Res2017;23:6487-97

[31] Christensen E,Sethi H.Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free dna in patients with urothelial bladder carcinoma.J Clin Oncol2019;37:1547-57

[32] Shohdy KS,Cao Y.Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.Br J Cancer2022;126:430-9 PMCID:PMC8810988

[33] Grivas P,Pond GR.Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study.Eur Urol Oncol2020;3:695-9

[34] Agarwal N,Hahn AW.Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.Cancer2018;124:2115-24 PMCID:PMC6857169

[35] Grivas P,Sonpavde GP.Spectrum of FGFR2/3 alterations in cell-free DNA of patients with advanced urothelial carcinoma.BLC2021;7:143-8

[36] Xie Y,Chen L.MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis.Sci Rep2017;7:5619 PMCID:PMC5514092

[37] Stenehjem DD,Nkrumah MA.PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.Onco Targets Ther2018;11:5973-89 PMCID:PMC6157986

[38] Balar AV,Rosenberg JE.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet2017;389:67-76 PMCID:PMC5568632

[39] Udall M,Kenny J.PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.Diagn Pathol2018;13:12 PMCID:PMC5807740

[40] Loriot Y,Park SH.Erdafitinib in locally advanced or metastatic urothelial carcinoma.N Engl J Med2019;381:338-48

[41] De Luca A,Rachiglio AM.FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention.Int J Mol Sci2020;21:6856 PMCID:PMC7555921

[42] Research C for DE and FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma [Last accessed on 3 Aug 2022].

[43] Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS. The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer.Eur Urol2019;75:435-44 PMCID:PMC6697269

[44] Zahoor H.The cancer immunogram: a pledge for a comprehensive biomarker approach for personalized immunotherapy in urothelial cancer.Eur Urol2019;75:445-7

[45] Fraune C,Hube-Magg C.MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass.Urol Oncol2020;38:488-95

[46] Sarfaty M,Al-ahmadie H.Microsatellite instability (MSI-H) in metastatic urothelial carcinoma (mUC): a biomarker of divergent responses to systemic therapy.JCO2020;38:566-566

[47] Teo MY,Ostrovnaya I.Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers.J Clin Oncol2018;36:1685-94 PMCID:PMC6366295

[48] Powles T,Loriot Y.Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN bladder 100 trial.Nat Med2021;27:2200-11

[49] Bellmunt J,Fradet Y.Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials.Clin Cancer Res2022;28:2050-60

[50] Chu CE,Egusa EA.Heterogeneity in.NECTIN427:5123-30 PMCID:PMC8634828

[51] Hoffman-Censits JH,Parimi V.Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes.Appl Immunohistochem Mol Morphol2021;29:619-25 PMCID:PMC8429050

[52] Jindal T,Chou J.Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC).JCO2022;40:531-531

[53] Koshkin VS,James M.Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.Cancer2022;128:1194-205

[54] Chou J,Sjöström M.TROP2 Expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells.Eur Urol Oncol2022:S2588-9311(21)00215

[55] Loriot Y,Petrylak D.700P efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC).Ann Oncol2021;32:S712-3

[56] Geller NL,Penenberg D,Yagoda A.Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy.Cancer1991;67:1525-31

[57] Lin CC,Huang CY.Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.Urology2007;69:479-84

[58] Apolo AB,Halabi S.Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.J Natl Cancer Inst2013;105:499-503 PMCID:PMC3691944

[59] Pond GR,Bellmunt J.A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.BJU Int2014;113:E137-43

[60] Salah S,Rozzi A.Second-line chemotherapy for metastatic urothelial carcinoma: importance of lymph node-only metastasis as a prognostic factor and construction of a prognostic model.Clin Genitourin Cancer2016;14:255-60

[61] Sonpavde G,Rosenberg JE.Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.J Urol2016;195:277-82 PMCID:PMC5025874

[62] Necchi A,Lo Vullo S.Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC).Eur Urol2017;71:281-9 PMCID:PMC5576985

[63] Nelson AA,Lemke EA.Early bone metastases are associated with worse outcomes in metastatic urothelial carcinoma.BLC2021;7:33-42